# Pfizer (PFE) Financial Model Free Excel 3-statement financial model and company analysis for Pfizer. - Canonical: https://finamodel.com/companies/pfizer - Industry: Pharmaceuticals - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/PFE.xlsx ## Model Purpose This model provides a sum-of-the-parts equity valuation and pipeline scenario analysis to determine if Pfizer's current share price accurately reflects the long-term growth potential of its Seagen oncology acquisition and internal pipeline against the impending loss of exclusivity (LOE) cliffs for key drugs like Eliquis and Ibrance. ## Company Overview Pfizer Inc. is a premier global biopharmaceutical company that discovers, develops, manufactures, and sells healthcare products, including innovative medicines and vaccines. The company operates a highly diversified portfolio across multiple therapeutic areas, transitioning from a period of unprecedented COVID-19 driven revenue to a focus on oncology and internal medicine. Business segments include: * **Primary Care (approx. 45-50% of revenue):** Includes internal medicine, vaccines (Prevnar family), and COVID-19 products (Comirnaty, Paxlovid). * **Specialty Care (approx. 20-25% of revenue):** Includes treatments for rare diseases, inflammation, and immunology (Vyndaqel, Xeljanz). * **Oncology (approx. 20-25% of revenue):** Includes legacy Pfizer oncology (Ibrance, Xtandi) and the recently acquired Seagen antibody-drug conjugate (ADC) portfolio. * **Business Innovation / PC1 (approx. 2-3% of revenue):** Pfizer CentreOne contract manufacturing and active pharmaceutical ingredient sales. Key geographies: The United States is the largest market (approx. 60% of revenue), followed by other developed markets and emerging markets (including China). Business model type: Asset-heavy manufacturing combined with highly intellectual property-driven R&D and commercialisation. Competitive position: Top 5 global pharmaceutical company by revenue, competing with Johnson & Johnson, Merck, AbbVie, and Novartis. Recent major events: Acquired Seagen for $43 billion in December 2023 to transform its oncology pipeline; executed a major cost-realignment programme targeting $4.5 billion in net cost savings by the end of 2025; experienced a massive normalisation in COVID-19 revenues resulting in significant non-cash revenue reversals in late 2023 and early 2024. ## Revenue Deep Dive ### Primary Care * **Segment name:** Primary Care * **Revenue driver formula:** (Vaccine Doses Administered x Net Price per Dose) + (Prescription Volume x Net Realised Price) * **Historical growth rate:** Highly volatile due to COVID-19; non-COVID operational growth typically 3-5% CAGR. * **Key growth levers and headwinds:** Prevnar 20 uptake in adult and paediatric populations; Nurtec ODT growth in migraine; headwind from the continued normalisation of Comirnaty and Paxlovid demand. * **Pricing dynamics:** Heavily contracted with governments (for COVID products) and managed care organisations; subject to US Inflation Reduction Act (IRA) pricing pressures. * **Revenue recognition notes:** Product sales recognised upon transfer of control; Paxlovid experienced a $3.5 billion non-cash revenue reversal in Q4 2023 due to US government returns, partially adjusted in Q1 2024. * **Seasonality:** Q3 and Q4 are typically stronger due to the autumn/winter respiratory vaccination season. ### Specialty Care * **Segment name:** Specialty Care * **Revenue driver formula:** Patient Population x Market Share x Annual Treatment Cost x Compliance Rate * **Historical growth rate:** 5-8% CAGR. * **Key growth levers and headwinds:** Vyndaqel family (transthyretin amyloid cardiomyopathy) is a major growth driver; headwinds from Xeljanz safety label changes and upcoming LOEs. * **Pricing dynamics:** High-cost, low-volume rare disease pricing model; high reliance on patient assistance programmes and specialty pharmacy distribution. * **Revenue recognition notes:** Standard gross-to-net deductions for rebates, chargebacks, and co-pay assistance. * **Seasonality:** Q1 is often the weakest due to US insurance deductible resets (the "co-pay effect"). ### Oncology * **Segment name:** Oncology * **Revenue driver formula:** (Incident Patient Population x Duration of Therapy x Net Price) + Alliance Revenue (Profit Share) * **Historical growth rate:** Flat to low single digits prior to Seagen; expected to grow 10%+ CAGR with Seagen integration. * **Key growth levers and headwinds:** Integration and label expansion of Seagen ADCs (Padcev, Adcetris, Tukysa); severe headwind from Ibrance competitive pressures and impending LOE; Xtandi continued growth. * **Pricing dynamics:** High pricing power for novel mechanisms, though combination therapies face pricing scrutiny. * **Revenue recognition notes:** Includes direct product sales and alliance revenues (e.g., Xtandi profit share with Astellas). * **Seasonality:** Generally not seasonal. ### Business Innovation * **Segment name:** Pfizer CentreOne (PC1) * **Revenue driver formula:** Contracted Manufacturing Volume x Toll Rate * **Historical growth rate:** 2-4% CAGR. * **Key growth levers and headwinds:** Utilisation of excess manufacturing capacity; headwind from general biotech funding slowdown affecting contract development. * **Pricing dynamics:** Long-term contractual pricing with raw material pass-throughs. * **Revenue recognition notes:** Recognised over time as manufacturing services are rendered. * **Seasonality:** Minimal seasonality; driven by client batch scheduling. ## Cost Structure ### Variable Costs / COGS * **Line-by-line breakdown:** Raw materials, active pharmaceutical ingredients (API), direct manufacturing labour, overhead, royalties paid to third parties, and inventory write-offs. * **Gross margin range:** 68% to 75% (Adjusted gross margin was 74% in 2024). * **Key input costs and commodity exposures:** Specialised chemical precursors, biological materials, and energy costs for manufacturing facilities. * **How COGS scales with revenue:** Step-function scaling based on facility utilisation; highly sensitive to product mix (e.g., alliance revenues have 100% gross margin, while manufactured products have standard COGS). ### Operating Expenses * **R&D:** Typically 15-18% of revenue ($10.8 billion in 2024). Covers basic research, clinical trials (Phases I-III), and regulatory submissions. Expensed as incurred unless acquired with alternative future use. * **SG&A:** Typically 20-25% of revenue. Includes sales force deployment, direct-to-consumer advertising, and corporate overhead. * **Depreciation & Amortisation:** Significant amortisation of intangible assets (approx. 5-7% of revenue) due to historical acquisitions (Wyeth, Hospira, Seagen). * **Stock-Based Compensation:** Approx. 1-2% of revenue. * **Restructuring / one-time charges:** Frequent and material. The current cost realignment programme targets $4.5 billion in savings by 2025, generating significant upfront severance and facility exit charges. ### Margin Profile * **Gross margin:** 70-75% (Adjusted). * **EBITDA margin:** 30-35% (excluding COVID peak years). * **Operating margin:** 25-30% (Adjusted). * **Net margin:** 20-25% (Adjusted). * **Margin trend:** Expanding post-2023 trough as COVID inventory write-offs subside and the $4.5 billion cost realignment programme flows through the P&L. ## Balance Sheet Structure * **Total assets:** Approx. $220-230 billion. * **Key asset categories:** Identifiable intangible assets, goodwill, property, plant and equipment, and accounts receivable. * **Goodwill & intangibles as % of total assets:** Very high (approx. 45-55%) following the $43 billion Seagen acquisition and previous deals (Biohaven, GBT). * **Working capital profile:** * **Days Sales Outstanding (DSO):** 60-70 days. * **Days Inventory Outstanding (DIO):** 200-250 days (pharma manufacturing requires long lead times and safety stock). * **Days Payable Outstanding (DPO):** 50-60 days. * **Net working capital as % of revenue:** 15-20%. * **Is working capital positive or negative?** Positive. The company requires significant inventory investment to support global supply chains. * **PP&E:** Approx. $20-25 billion. Consists of global manufacturing facilities, R&D laboratories, and corporate offices. Useful lives range from 15-40 years for buildings and 5-20 years for machinery. * **Right-of-use assets / operating leases:** Approx. $1.5-2.0 billion; material but not a primary driver of leverage. ## Capital Expenditure & Investment * **Capex as % of revenue:** 4-6% ($2.5-$3.5 billion annually). * **Maintenance capex vs. growth capex:** Roughly 40% maintenance / 60% growth (capacity expansion for biologics and sterile injectables). * **Major capex programmes underway or planned:** Upgrading manufacturing networks for mRNA technology and ADC manufacturing post-Seagen. * **Capitalised software / development costs:** Minimal relative to physical PP&E; clinical trial costs are not capitalised. * **M&A pattern:** Transformational acquirer (Seagen for $43 billion) mixed with frequent bolt-on acquisitions (Biohaven, Global Blood Therapeutics, Arena Pharmaceuticals). * **Typical acquisition multiple paid:** Often 5-10x peak sales for clinical-stage or early-commercial biotech assets. ## Debt & Capital Structure * **Total debt:** Approx. $60-65 billion (elevated due to Seagen acquisition funding). * **Debt/EBITDA ratio:** Currently elevated (approx. 4.0x); management target is to delever to 3.25x gross leverage by the end of 2025. * **Credit rating:** A1 (Moody's) / A (S&P). * **Key debt instruments:** Senior unsecured notes (bonds) and commercial paper for working capital. * **Maturity profile:** Well-laddered, with average maturity exceeding 10 years. * **Interest rate profile:** Predominantly fixed-rate bonds; weighted average cost of debt is approx. 3.5-4.5%. * **Covenants:** Standard investment-grade covenants; no restrictive financial maintenance covenants. * **Share repurchase programme:** Paused for 2024 to prioritise deleveraging; historical authorisation exists but will not be utilised until the 3.25x leverage target is met. * **Dividend policy:** Highly committed to the dividend. 2024 dividend was $1.68 per share (approx. $9.5 billion total). Payout ratio is currently high relative to GAAP earnings but manageable on adjusted cash flows. ## Cash Flow Characteristics * **Operating cash flow conversion:** Typically 1.0x to 1.2x of Adjusted Net Income. * **Free cash flow margin:** 15-20% of revenue in normalised years. * **Major non-cash items that bridge net income to OCF:** Amortisation of intangibles (massive driver), depreciation, stock-based compensation, and deferred taxes. * **Working capital cash flow impact:** Often a use of cash during product launch phases; inventory build was a major drag during the COVID scale-up and subsequent wind-down. * **Capex intensity:** Moderate (4-6% of revenue), making the business highly free cash flow generative once R&D is funded. * **Cash tax rate vs. GAAP effective tax rate:** Cash taxes are often lower than GAAP taxes due to R&D tax credits, foreign earnings mix, and timing of deductible intangible amortisation. Effective tax rate is typically 14-16%. ## Sheet Structure 1. **Assumptions:** Hardcoded inputs for macroeconomic drivers, tax rates, WACC, and scenario toggles. 2. **Product Revenue Build:** Line-by-line forecasting for top 15 drugs (Comirnaty, Paxlovid, Eliquis, Prevnar, Vyndaqel, Ibrance, Xtandi, Nurtec, Padcev, Adcetris, etc.) using Volume x Price or market share mechanics. 3. **Segment Revenue:** Aggregation of the Product Revenue Build into Primary Care, Specialty Care, Oncology, and PC1. 4. **Income Statement:** Consolidated P&L mirroring the 10-K, including adjustments to bridge GAAP to Non-GAAP (Adjusted) earnings. 5. **Working Capital:** Schedules for Accounts Receivable, Inventory, and Accounts Payable driven by DSO, DIO, and DPO. 6. **PP&E and Intangibles:** Waterfall schedules for capex, depreciation, and the heavy amortisation burden of acquired intangibles. 7. **Debt Schedule:** Tranche-by-tranche bond maturity schedule, interest expense calculation, and commercial paper tracking. 8. **Cash Flow Statement:** Indirect method starting from Net Income, adjusting for non-cash items, working capital changes, and capex. 9. **Balance Sheet:** Standard balancing statement linking Assets to Liabilities and Equity. 10. **Valuation (DCF):** Unlevered free cash flow calculation, terminal value (using Gordon Growth), and bridge to equity value per share. 11. **LOE & Pipeline Scenarios:** Sensitivity tables showing the impact of Eliquis/Ibrance patent expiries and probability-weighted pipeline approvals. ## Key Financial Relationships 1. `Total Revenue = Primary Care Revenue + Specialty Care Revenue + Oncology Revenue + PC1 Revenue` 2. `Primary Care Revenue = Comirnaty Revenue + Paxlovid Revenue + Prevnar Family Revenue + Eliquis Alliance Revenue + Other Primary Care` 3. `Oncology Revenue = Legacy Pfizer Oncology + Seagen Portfolio Revenue` 4. `Adjusted Gross Profit = Total Revenue - Adjusted Cost of Sales (excluding acquisition-related amortisation)` 5. `Adjusted Operating Income = Adjusted Gross Profit - Adjusted R&D - Adjusted SG&A` 6. `Reported Net Income = Adjusted Net Income - Amortisation of Intangibles - Restructuring Charges - Acquisition-related Costs` 7. `Free Cash Flow = Cash from Operations - Capital Expenditures` 8. `Gross Leverage Ratio = Total Debt / Adjusted EBITDA` 9. `Dividend Payout = Total Dividends Paid / Adjusted Net Income` 10. `Amortisation Expense = Beginning Intangible Assets x Blended Amortisation Rate (approx. 8-10% given useful lives)` ## Cross-Sheet Dependencies * The **Product Revenue Build** is the critical foundation; it feeds directly into the **Segment Revenue** sheet. * **Segment Revenue** drives the top line of the **Income Statement**. * The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement**. * Revenue and COGS from the **Income Statement** drive the **Working Capital** sheet (Accounts Receivable and Inventory). * The **Debt Schedule** calculates Interest Expense, which feeds back into the **Income Statement** (creating a potential circularity if debt paydown is linked to cash sweeps; use a circularity breaker toggle). * The **Cash Flow Statement** determines the ending cash balance and debt paydown capacity, which feed the **Balance Sheet**. * The **Balance Sheet** must balance, serving as the ultimate mathematical check for the model. ## Sign Convention * **Revenues and Assets:** Entered and displayed as positive numbers. * **Expenses (COGS, R&D, SG&A):** Entered as positive numbers in assumptions, but subtracted in formulas (e.g., `Gross Profit = Revenue - COGS`). * **Liabilities and Equity:** Entered and displayed as positive numbers. * **Cash Flow Statement:** Cash inflows are positive; cash outflows (capex, dividends, debt repayment) are negative. * **Contra-revenue (rebates, returns):** Entered as positive numbers but subtracted from Gross Sales to reach Net Revenue. ## Things Most Likely to Go Wrong 1. **COVID-19 Revenue Volatility:** Paxlovid and Comirnaty revenues have swung wildly. Do not straight-line historical growth; model these as stabilising at a low baseline. 2. **GAAP vs. Non-GAAP Confusion:** Pfizer's GAAP earnings are heavily depressed by intangible amortisation and restructuring. The model must forecast Adjusted Diluted EPS to align with management guidance and consensus. 3. **Alliance Revenue Margins:** Eliquis and Xtandi are recorded as alliance revenues (profit shares). These drop straight to the bottom line with effectively 100% gross margin. Applying a standard corporate COGS margin to these lines will severely understate profitability. 4. **Seagen Integration:** Historical Oncology segment data prior to 2024 does not include Seagen. Year-over-year comparisons for 2024 vs 2023 are skewed. 5. **LOE Cliffs:** Eliquis faces loss of exclusivity later in the decade. The model must include a steep revenue drop-off (often 80-90% erosion over 2 years) for this product starting in the LOE year. 6. **Restructuring Add-backs:** The $4.5 billion cost realignment programme will cause elevated one-time charges through 2025. These must be excluded from free cash flow proxies used for valuation. 7. **Share Count:** Pfizer issued debt, not equity, for Seagen. Do not assume massive share dilution, but do account for standard stock-based compensation creep. 8. **Interest Expense Drag:** The $43 billion Seagen acquisition added significant debt. Interest expense is materially higher post-2023 and must be modelled accurately based on the new debt load. ## Validation Checks 1. "Adjusted Gross Margin should be in the 70-75% range; flag if outside this band." 2. "R&D as a % of revenue should remain between 15-18% to support the pipeline." 3. "Total Debt should decrease year-over-year through 2025 as the company prioritises deleveraging to hit its 3.25x target." 4. "Dividend per share must not decrease (management has a strict progressive/stable dividend policy); check that DPS is >= $1.68." 5. "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period." 6. "Eliquis revenue must decline by at least 50% in the first full year following its modelled loss of exclusivity." 7. "Effective tax rate on Adjusted Income should be 14-16%." 8. "Capex as % of revenue should run 4-6%." ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Total Revenue Growth (ex-COVID) | 6.0 | % | Management guidance for operational growth excluding COVID products | | Comirnaty Revenue (2025E) | 3.5 | $ Billions | Stabilised endemic vaccination rate assumption | | Paxlovid Revenue (2025E) | 2.5 | $ Billions | Stabilised endemic treatment rate assumption | | Adjusted Gross Margin | 74.0 | % | Actual 2024 adjusted gross margin | | R&D Expense Margin | 17.0 | % | Aligns with $10.8B actual 2024 spend on $63.6B revenue | | SG&A Expense Margin | 22.0 | % | Historical average adjusted for cost realignment savings | | Effective Tax Rate (Adjusted) | 15.0 | % | Management guidance range | | Days Sales Outstanding (DSO) | 65 | Days | Historical average based on AR balance | | Days Inventory Outstanding (DIO) | 220 | Days | Historical average reflecting complex biologics supply chain | | Days Payable Outstanding (DPO) | 55 | Days | Historical average | | Capex as % of Revenue | 5.0 | % | Historical average | | Dividend per Share | 1.68 | $ | Actual 2024 dividend, assumed flat/slight growth | | Diluted Shares Outstanding | 5,703 | Millions | Actual Q4 2024 weighted average shares | | Cost of Debt | 4.2 | % | Weighted average interest rate on outstanding bonds | | WACC | 7.5 | % | Standard large-cap pharma discount rate | | Terminal Growth Rate | 1.5 | % | Conservative long-term growth reflecting continuous patent cliffs | ## Data Sources & Benchmarks * **SEC Filings:** Pfizer Investor Relations website (investors.pfizer.com) for 10-K, 10-Q, and 8-K earnings releases. * **Key Peers for Benchmarking:** Johnson & Johnson (JNJ), Merck & Co. (MRK), AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS). * **Industry Data Sources:** EvaluatePharma (for consensus pipeline NPV and LOE dates), IQVIA (for monthly prescription volume data and pricing trends). * **Clinical Trial Data:** ClinicalTrials.gov for tracking Pfizer's Phase III pipeline progress. ## Sources * Pfizer Inc. Q4 2024 Earnings Release and Financial Schedules (February 4, 2025). * Pfizer Inc. 2024 Annual Report on Form 10-K. * Pfizer Investor Relations Presentations (2024 Cost Realignment Programme updates). * SEC EDGAR Database for historical segment reporting and Seagen acquisition filings. --- ## Frequently asked questions ### What does Pfizer Inc. do? Pfizer Inc. is a premier global biopharmaceutical company that discovers, develops, manufactures, and sells healthcare products, including innovative medicines and vaccines. The company operates a highly diversified portfolio across multiple therapeutic areas, with a current focus on oncology and internal medicine. ### What are Pfizer's primary revenue drivers? Pfizer's revenue is largely driven by its Primary Care segment, which includes internal medicine, vaccines like the Prevnar family, and COVID-19 products such as Comirnaty and Paxlovid. Specialty Care and Oncology segments also contribute significantly, with the recent Seagen acquisition bolstering its oncology portfolio. ### What is the assumed revenue growth rate for Pfizer in the financial model? The provided financial model assumes a revenue growth rate of approximately 9.85% for Pfizer. This growth rate is intended to capture the long-term potential from the Seagen oncology acquisition and internal pipeline, balanced against the impact of upcoming loss of exclusivity for key drugs. ### How does the financial model approach Pfizer's equity valuation? The financial model uses a sum-of-the-parts equity valuation and pipeline scenario analysis to assess Pfizer. Its purpose is to determine if the current share price accurately reflects the long-term growth potential from the Seagen oncology acquisition and internal pipeline, considering impending patent expirations. ### Can I download an Excel financial model for Pfizer? Yes, an Excel financial model for Pfizer is available for download. This general corporate model provides a forecast horizon from FY2026 to FY2030 and includes key assumptions for revenue growth, margins, and capital expenditures. ### What is the significance of goodwill and intangible assets on Pfizer's balance sheet? Goodwill and identifiable intangible assets represent a very high proportion of Pfizer's total assets, approximately 45-55%. This reflects the company's strategy as a transformational acquirer, highlighted by the $43 billion Seagen acquisition and other significant deals. [Interactive forecast calculator](https://finamodel.com/companies/pfizer/forecast)